Oramed Pharmaceuticals Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.682 million compared to USD 0.682 million a year ago. Net loss was USD 7.06 million compared to USD 7.26 million a year ago. Basic earnings per share from continuing operations was USD 0.18 compared to USD 0.21 a year ago.
For the nine months, sales was USD 2.02 million compared to USD 2.02 million a year ago. Net loss was USD 28.02 million compared to USD 16.74 million a year ago. Basic earnings per share from continuing operations was USD 0.72 compared to USD 0.54 a year ago.